<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03128593</url>
  </required_header>
  <id_info>
    <org_study_id>JR-141-101</org_study_id>
    <nct_id>NCT03128593</nct_id>
  </id_info>
  <brief_title>A Study of JR-141 in Patients With Mucopolysaccharidosis Type II</brief_title>
  <official_title>A Phase I/II Study of JR-141 in Patients With Mucopolysaccharidosis Type II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JCR Pharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>JCR Pharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study in patients with mucopolysaccharidosis type II (MPS II) is below,&#xD;
&#xD;
        -  to collect the safety information of JR-141&#xD;
&#xD;
        -  to evaluate the plasma pharmacokinetics of JR-141&#xD;
&#xD;
        -  to explore the efficacy of JR-141 on MPS II-related central nervous system symptoms and&#xD;
           general symptoms&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 30, 2017</start_date>
  <completion_date type="Actual">October 4, 2017</completion_date>
  <primary_completion_date type="Actual">October 4, 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Adverse Events</measure>
    <time_frame>4 weeks</time_frame>
    <description>Adverse events&#xD;
Laboratory tests&#xD;
Vital signs&#xD;
12-lead electrocardiogram&#xD;
Antibody&#xD;
Infusion associated reaction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetic parameter [Maximum Plasma Concentration [Cmax]]</measure>
    <time_frame>4 weeks</time_frame>
    <description>Plasma concentration of JR-141</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetic parameter [Area Under the Curve [AUC]]</measure>
    <time_frame>4 weeks</time_frame>
    <description>Plasma concentration of JR-141</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary and serum heparan sulfate (HS) /dermatan sulfate (DS)</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HS/DS in CSF</measure>
    <time_frame>4 weeks</time_frame>
    <description>JR-141 concentration in CSF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary total GAG</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver and spleen volumes</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac function</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Mucopolysaccharidosis II</condition>
  <arm_group>
    <arm_group_label>Experimental: JR-141</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JR-141</intervention_name>
    <description>IV infusion (lyophilized powder), 0.01-2.0 mg/kg/week</description>
    <arm_group_label>Experimental: JR-141</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged 6 years or older at the time of informed consent.&#xD;
&#xD;
          -  Patients diagnosed with MPS II.&#xD;
&#xD;
          -  Patients who have received idursulfase (0.5 mg/kg/week) continuously for at least 12&#xD;
             weeks until the initial dose of JR-141.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a history of hematopoietic stem cell transplantation, excluding those&#xD;
             who need enzyme replacement therapy even after hematopoietic stem cell&#xD;
             transplantation.&#xD;
&#xD;
          -  Patients in whom lumbar puncture cannot be performed.&#xD;
&#xD;
          -  Patients who have developed serious drug allergy or hypersensitivity that is&#xD;
             inappropriate for participation in the study.&#xD;
&#xD;
          -  Patients who have received other investigational products within 4 months before&#xD;
             enrollment in the study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Gifu Clinical site</name>
      <address>
        <city>Gifu</city>
        <zip>501-1194</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukuoka Clinical site</name>
      <address>
        <city>Kurume</city>
        <zip>830-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo clinical site1</name>
      <address>
        <city>Minato</city>
        <zip>105-8471</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Clinical site1</name>
      <address>
        <city>Osaka</city>
        <zip>545-8586</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saitama Clinical site</name>
      <address>
        <city>Saitama</city>
        <zip>330-8777</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo clinical site2</name>
      <address>
        <city>Setagaya</city>
        <zip>157-8535</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Clinical site2</name>
      <address>
        <city>Suita</city>
        <zip>157-8535</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tottori Clinical site</name>
      <address>
        <city>Yonago</city>
        <zip>683-8504</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/30595526/</url>
    <description>Iduronate-2-Sulfatase with Anti-human Transferrin Receptor Antibody for Neuropathic Mucopolysaccharidosis II: A Phase 1/2 Trial</description>
  </link>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>April 10, 2017</study_first_submitted>
  <study_first_submitted_qc>April 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2017</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucopolysaccharidosis II</mesh_term>
    <mesh_term>Mucopolysaccharidoses</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

